Gastroenterology Research and Practice / 2019 / Article / Tab 1

Research Article

Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure

Table 1

Baseline demographic, clinical, and laboratory characteristics of HB-ACLF survivors and nonsurvivors in the training set.

TotalSurvivorsNonsurvivors

Number604515
Age (yr)44 (25-67)42 (25-63)51 (31-67)≤0.001
Sex, male (, %)53 (88.3)40 (88.9)13 (86.7)0.816
HBeAg positive (, %)39 (65.0)28 (62.2)11 (73.3)0.435
HBV-DNA (lg copies/ml)6.93 (2.97-9.02)7.08 (2.97-9.02)6.66 (3.63-9.00)0.335
Serum bilirubin (mg/dl)18.88 (7.39-36.68)18.58 (8.12-36.68)21.43 (7.39-28.40)0.242
Serum albumin (g/l)29 (18-38)30 (18-38)27 (23-33)0.023
ALT (U/ml)644.5 (64-3291)515 (64-3291)677.8 (206-1227)0.389
AST (U/ml)365.3 (45-2265)317 (45-2265)590.9 (126-1231)0.099
INR2.21 (1.66-4.60)2.14 (1.66-3.44)2.66 (1.73-4.60)0.043
Baseline sCr (mg/dl)65 (32.83-108)64 (36-108)70 (32.83-99)0.191
Leukocyte count (109/l)6.64 (2.69-13.59)6.65 (2.69-13.59)6.28 (3.63-12.37)0.959
Platelet count (109/l)109 (44-309)109 (44-309)105 (49-166)0.585
MELD score23 (13-35)23 (13-29)25 (20-35)0.029
CLIF-C OF9 (7-12)9 (7-12)10 (8-12)0.001
CRP (ng/ml)6.89 (1.25-67.58)6.04 (1.31-67.58)12.71 (1.25-29.50)≤0.001
PCT (ng/ml)0.45 (0.12-5.90)0.41 (0.14-5.90)0.82 (0.12-2.0)≤0.001
SuPAR (ng/ml)12.61 (2.25-68.44)10.61 (2.29-68.44)25.68 (2.25-42.61)≤0.001
Complications (, %)
 Infection45 (75)31 (68.9)14 (93.3)0.086
 Gastrointestinal bleeding5 (8.3)0 (0)5 (33.3)0.001
Hepatic encephalopathy18 (30)9 (20)9 (60)0.016
 HRS6 (10)0 (0)6 (40)≤0.001

: number; yr: year; sCr: serum creatinine; MELD: model for end-stage liver disease; CLIF-C OF: chronic liver failure consortium organ failure; CRP: C-reactive protein; PCT: procalcitonin; HRS: hepatorenal syndrome.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.